BMJ 2003;326:620 ( 22 March )
News extra
Possible link between flu jab and Guillain-Barré
syndrome under investigation
Washington
Charles Marwick
The US Institute of Medicine’s immunisation safety
review committee has been investigating whether the influenza vaccine
might carry a risk of the demyelinating disorder Guillain-Barré syndrome.
A sharp increase in cases of the disorder occurred in
1993-4 after immunisation . There were 74 cases in 1994, compared with
only 37 cases in 1993 and 23 in 1991. Although the number of reports of
vaccine associated cases of the syndrome has remained low in recent
years—between 20 and 40—the sudden increase in 1994 raised concerns about
vaccine safety.
In a fact finding session earlier this month, the
committee heard reviews of studies since 1976, when the numbers of
vaccine associated cases of the syndrome stopped the US immunisation
campaign against "swine flu." By then, 45 million people had been
vaccinated. Ultimately, 581 cases of Guillain-Barré syndrome were
reported that year, said the Centers for Disease Control and Prevention
(CDC) in Atlanta, Georgia.
Initial studies suggested a causal relation between
Guillain-Barré syndrome and the vaccine. Subsequently this was challenged
on several grounds, including that the cases had been gathered by public
health officers who had not been trained to diagnose the syndrome;
reports were not based on medical records; some cases accepted by the CDC
failed to meet the criteria for the syndrome; and the publicity over the
possible link had biased the reporting of cases.
A later study, in 1991, reviewed all the cases of the
syndrome in adults (whether vaccinated or unvaccinated) from two states.
Using a standard definition of Guillain-Barré syndrome, it rejected 29%
of them, said Dr Robert Chen of the CDC’s immunisation safety branch.
A 1998 study, summarised for the committee, showed
that if there was a risk of flu vaccine causing the syndrome, it was
extremely small. Dr Tamar Lasky from the University of Maryland School of
Medicine put it at between 1 and 2 cases per million vaccinated persons a
year.
One possible cause is that flu vaccine contains
Campylobacter, said Dr Chen. He said that the vaccine is made in chicken
eggs and that 40-50% of chickens are infected with Campylobacter, which
is difficult to eradicate.
However, the syndrome can occur after various clinical
events, said neurologist Dr John Griffin from Johns Hopkins University
School of Medicine, Baltimore. He cited surgery, pregnancy, childbirth,
and "all sorts of non-specific infections."
Probably 70% of cases of the syndrome follow
something, he said. "But the robust associations are really restricted to
Campylobacter and to herpes viruses, and they include HIV, where there is
likely to be an altered immune state. It’s worth keeping in mind that
pharmacologic immunosuppression may also lead to Guillain-Barré
syndrome."
Dr Marie McCormick from Harvard School of Public
Health and chairwoman of the committee said the findings would be
published in two to three months.

Pol J Microbiol. 2004;53 Suppl:7-15. Related Articles,
Links
New approaches to development of mucosal vaccine against enteric
bacterial pathogens; preventing campylobacteriosis.
Jagusztyn-Krynicka EK, Wyszynska A, Raczko A.
Department of Bacterial Genetics, Institute of Microbiology, Warsaw
University, Warsaw, Poland.
Although vaccination, after having been more than 200 years in medical
practice, has proven to be the most effective and the cheapest way to
prevent infectious diseases, they remain still the main cause of human
premature deaths. As many pathogens enter the human body through the
mucosal surfaces, the mucosal way of immunization is considered to be the
most promising strategy to decrease the number of human infections.
Moreover, the oral delivery system eliminates the necessity of injection
what is extremely important for pediatric immunization programs. However,
most of recently constructed subunit vaccines based on purified
bacterial/viral antigens are rather poorly immunogenic. This review
presents some novel ways to enhance and modulate host immune responses by
combining antigens with specific adjuvants or by employing specific
delivery systems. We also discuss some recent technologies, based on
mining the genomic sequences of bacterial pathogens, which accelarate and
improve identification of new candidates for vaccine construction. As an
example, we focus on the progress in the development of vaccine against
Campylobacter spp. Campylobacter jejuni is now recognized as a leading
cause of bacterial enteritis in human.
PMID: 15787191 [PubMed - in process]